Dispatch Bio

Executive Summary

Dispatch Biotherapeutics (Dispatch Bio) is a privately held, early-stage biotechnology company founded in 2021 and headquartered in Cambridge, Massachusetts. The company is dedicated to developing novel immunotherapies for solid tumors, leveraging its proprietary Flare platform. While immunotherapies have revolutionized blood cancer treatment, their efficacy in solid tumors remains limited. Dispatch Bio aims to address this gap by engineering antibodies and biologics that can better penetrate and activate immune responses within the tumor microenvironment. As a young company with no disclosed pipeline candidates or financial details, Dispatch Bio's progress and potential are currently opaque. Its success hinges on the ability of the Flare platform to differentiate from other immunotherapeutic approaches and attract partnerships or funding to advance into preclinical and clinical development.

Upcoming Catalysts (preview)

• TBDSeries A funding or partnership announcement40% success
• TBDPublication of preclinical data from Flare platform50% success
• 2026Establishment of scientific advisory board or key hires35% success